Teladoc Inc. (NYSE:TDOC) VP Mark Hirschhorn sold 5,000 shares of Teladoc stock in a transaction dated Monday, October 17th. The stock was sold at an average price of $15.52, for a total value of $77,600.00. Following the transaction, the vice president now directly owns 268,387 shares in the company, valued at $4,165,366.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of Teladoc Inc. (NYSE:TDOC) traded down 1.21% during midday trading on Wednesday, reaching $16.35. The company’s stock had a trading volume of 81,618 shares. The company’s market cap is $747.28 million. Teladoc Inc. has a 12 month low of $9.08 and a 12 month high of $22.00. The stock has a 50-day moving average of $17.90 and a 200 day moving average of $14.82.

Teladoc (NYSE:TDOC) last released its quarterly earnings data on Wednesday, August 3rd. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.39) by $0.01. Teladoc had a negative return on equity of 33.97% and a negative net margin of 60.88%. The company earned $26.50 million during the quarter, compared to analysts’ expectations of $28.20 million. During the same period last year, the firm posted ($0.46) earnings per share. The business’s revenue was up 44.9% on a year-over-year basis. On average, analysts predict that Teladoc Inc. will post ($1.45) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Teladoc (NYSE:TDOC)

TDOC has been the topic of a number of research analyst reports. FBR & Co reaffirmed an “outperform” rating and set a $35.00 target price on shares of Teladoc in a report on Tuesday, June 28th. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $22.00 target price (up from $20.00) on shares of Teladoc in a report on Monday, July 11th. Zacks Investment Research raised Teladoc from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a report on Monday, July 25th. Deutsche Bank AG lowered their target price on Teladoc from $21.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday, August 4th. Finally, Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and set a $24.00 target price (down from $25.00) on shares of Teladoc in a report on Friday, August 5th. One analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $22.90.

A number of hedge funds have recently added to or reduced their stakes in TDOC. BlackRock Group LTD boosted its stake in Teladoc by 1.1% in the first quarter. BlackRock Group LTD now owns 249,378 shares of the company’s stock valued at $2,394,000 after buying an additional 2,678 shares during the last quarter. Prudential Financial Inc. boosted its stake in Teladoc by 32.2% in the first quarter. Prudential Financial Inc. now owns 192,800 shares of the company’s stock valued at $1,851,000 after buying an additional 47,000 shares during the last quarter. California State Teachers Retirement System boosted its stake in Teladoc by 116.8% in the second quarter. California State Teachers Retirement System now owns 43,509 shares of the company’s stock valued at $697,000 after buying an additional 23,438 shares during the last quarter. Harbourvest Partners LLC purchased a new stake in Teladoc during the first quarter valued at $436,000. Finally, BlackRock Inc. boosted its stake in Teladoc by 1.0% in the first quarter. BlackRock Inc. now owns 59,460 shares of the company’s stock valued at $571,000 after buying an additional 560 shares during the last quarter. 40.46% of the stock is owned by institutional investors and hedge funds.

About Teladoc

Teladoc, Inc, together with its subsidiaries, is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company operates through health services segment. Its solution connects its Members, with its over 3,000 board-certified physicians and behavioral health professionals who treat a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.

5 Day Chart for NYSE:TDOC

Receive News & Stock Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related stocks with our FREE daily email newsletter.